Methods for Prediction and Prognosis of Cancer, and Monitoring Cancer Therapy

• US 20080311604A1
• Filed: 11/01/2006
• Published: 12/18/2008
• Est. Priority Date: 11/02/2005
• Status: Abandoned Application

• Current Assignee: Bayer Healthcare LLC (Bayer AG)
• Original Assignee: Bayer Healthcare LLC (Bayer AG)
• Inventors: Carney, Walter P., Hamer, Peter J., Elting, James J., Bigwood, Douglas
• Application Number:
  US12/091,899
• Publication Number:
  US 20080311604A1
• Time in Patent Office: Days
• US Class Current: 435/7.94
• CPC Class Codes: G01N 2333/475 Assays involving growth factors
• CPC Class Codes: G01N 2333/71 for growth factors; for growth regulators
• CPC Class Codes: G01N 33/57492 involving compounds localized on the membrane of tumor or cancer cells

Abstract

The present invention relates to biomarkers and the use of biomarkers for the prediction and prognosis of cancer as well as the use of biomarkers to monitor the efficacy of cancer treatment. Specifically, this invention relates to the use of soluble VEGF-R2 as a biomarker for multi-kinase inhibitors.

Claims

1. A method for monitoring the status of a disease associated with the soluble VEGF-R2 pathway in a patient, and/or monitoring how a patient with said disease is responding to a therapy comprising immunologically detecting and quantifying serial changes in soluble VEGF-R2 protein levels in patient samples taken over time, wherein increasing levels of soluble VEGF-R2 protein over time indicate disease progression or a negative response to said therapy, and wherein decreasing levels of soluble VEGF-R2 protein over time indicate disease remission or a positive response to said therapy.

2. The method of claim 1, wherein said therapy is selected from multi-kinase inhibitors, tyrosine kinase inhibitors, monoclonal antibodies, and bis-aryl ureas.

3. The method of claim 1, wherein said therapy is a VEGF pathway-directed therapy.

4. The method of claim 3, wherein said VEGF pathway-directed therapy is the tyrosine kinase inhibitor imatinib mesylate or the bis-aryl urea Sorafenib.

5. The method of claim 1, wherein said disease is a preneoplastic/neoplastic disease.

6. The method of claim 5, wherein said preneoplastic/neoplastic disease is selected from the group consisting of metastatic medulloblastoma, dermatofibrosarcoma protruberans, gastrointestinal stromal tumors, colorectal cancer, colon cancer, lung cancer, non-small-cell lung cancer, small-cell lung cancer, chronic myeloproliferative diseases, acute myelogenous leukemia, thyroid cancer, pancreatic cancer, bladder cancer, kidney cancer, melanoma, breast cancer, prostate cancer, ovarian cancer, cervical cancer, head-and-neck cancer, brain tumors, hepatocellular carcinoma, hematologic malignancies, and precancers leading to the aforementioned cancers.

7. The method of claim 1 which is further prognostic for said disease, wherein said levels of soluble VEGF-R2 protein in the patient'"'"'s samples are indicative of a better or poorer prognosis for said patient.

8. The method of claim 7, wherein said prognosis is a clinical outcome selected from the group consisting of response rate (RR), complete response (CR), partial response (PR), stable disease (SD), time to progression (TTP), progression free survival (PFS), overall survival (OS), and clinical benefit, which comprises complete response (CR), partial response (PR), and stable disease (SD).

9. The method of claim 1, wherein said patient'"'"'s samples are pretreatment samples.

10. The method of claim 1, wherein said patient sample is selected from the group consisting of blood, serum, plasma, urine, saliva, semen, breast exudate, cerebrospinal fluid, tears, sputum, mucous, lymph, cytosols, ascites, pleural effusions, amniotic fluid, bladder washes and bronchioalveolar lavages.

11. The method of claim 1, wherein said patient sample is serum or plasma.

12. The method of claim 1, wherein said immunological detection and quantitation is by an immunoassay in the form of a sandwich ELISA or equivalent assay.

13. The method of claim 12, wherein the sandwich ELISA or equivalent assay comprises the use of one or more monoclonal antibodies that selectively bind the soluble VEGF-R2 protein.

14. The method of claim 1, further comprising the use of an immunoassay to detect or detect and quantify levels of one or more other proteins in the patient'"'"'s samples.

15. The method of claim 14, wherein said other protein is or said other proteins are selected from the group consisting of inhibitors, oncoproteins, growth factor receptors, angiogenic factors, metastasis proteins, tumor markers, and tumor suppressors.

16. The method of claim 15 wherein said inhibitor is tissue inhibitor of metalloproteinase-1 (TIMP-1), said oncoproteins are selected from the group consisting of HER-2/neu and ras p21, said growth factor receptors are selected from the group consisting of epidermal growth factor receptor (EGFR) and platelet derived growth factor receptor alpha (PDGFR-α

), said angiogenic factor is vascular endothelial growth factor (VEGF), said metastasis protein is urokinase-type plasminogen activator (uPA), said tumor marker is carcinoembryonic antigen (CEA), and said tumor suppressor is p53.

17. A method of therapy selection for a human patient with a disease, comprising:

(a) immunologically detecting and quantifying the average level of soluble VEGF-R2 protein in control samples taken from individuals of a control population;

(b) immunologically detecting and quantifying serial changes in soluble VEGF-R2 protein levels in equivalent patient samples taken from the patient over time;

(c) comparing the levels of soluble VEGF-R2 protein in the patient'"'"'s samples to the average level of soluble VEGF-R2 protein in the control samples; and

(d) determining whether to use conventional therapy and/or VEGF pathway-directed therapy to treat the patient based upon the differences between the levels of soluble VEGF-R2 protein in the patient'"'"'s samples and the average level of soluble VEGF-R2 protein in the control samples, and in view of the serial changes among the levels of soluble VEGF-R2 protein in the patient'"'"'s samples.

18. The method of claim 17, wherein said patient'"'"'s samples are pretreatment samples.

19. The method of claim 17 which is further prognostic for said disease, wherein said levels of soluble VEGF-R2 protein in the patient'"'"'s samples are indicative of a better or poorer prognosis for said patient.

20. The method of claim 19, wherein said prognosis is a clinical outcome selected from the group consisting of response rate (RR), complete response (CR), partial response (PR), stable disease (SD), time to progression (TTP), progression free survival (PFS), overall survival (OS), and clinical benefit, which comprises complete response (CR), partial response (PR), and stable disease (SD).

21. The method of claim 17, wherein said disease is a preneoplastic/neoplastic disease.

22. The method of claim 21 which said preneoplastic/neoplastic disease is selected from the group consisting of metastatic medulloblastoma, dermatofibrosarcoma protruberans, gastrointestinal stromal tumors, colorectal cancer, colon cancer, lung cancer, non-small-cell lung cancer, small-cell lung cancer, chronic myeloproliferative diseases, acute myelogenous leukemia, thyroid cancer, pancreatic cancer, bladder cancer, kidney cancer, melanoma, breast cancer, prostate cancer, ovarian cancer, cervical cancer, head-and-neck cancer, brain tumors, hepatocellular carcinoma, hematologic malignancies, and precancers leading to the aforementioned cancers.

23. The method of claim 17, wherein the patient samples are from a cancer patient who has not responded to treatment.

24. The method of claim 17, further comprising the use of an immunoassay to detect or detect and quantify levels of one or more other proteins in the subject'"'"'s samples.

25. The method of claim 24, wherein said other protein is or said other proteins are selected from the group consisting of inhibitors, oncoproteins, growth factor receptors, angiogenic factors, metastasis proteins, tumor markers, and tumor suppressors.

26. The method of claim 25 wherein said inhibitor is tissue inhibitor of metalloproteinase-1 (TIMP-1), said oncoproteins are selected from the group consisting of HER-2/neu and ras p21, said growth factor receptors are selected from the group consisting of epidermal growth factor receptor (EGFR) and platelet derived growth factor receptor alpha (PDGFR-α

), said angiogenic factor is vascular endothelial growth factor (VEGF), said metastasis protein is urokinase-type plasminogen activator (uPA), said tumor marker is carcinoembryonic antigen (CEA), and said tumor suppressor is p53.

27. A diagnostic method to detect a disease associated with a VEGF pathway in a patient comprising:

(a) immunologically detecting and quantifying the average level of soluble VEGF-R2 protein in control samples taken from individuals of a control population;

(b) immunologically detecting and quantifying serial changes in soluble VEGF-R2 protein in samples of a patient sample taken from a patient over time; and

(c) comparing the levels of soluble VEGF-R2 protein in the patient'"'"'s samples to the average level of soluble VEGF-R2 protein in the control samples;

wherein a level of soluble VEGF-R2 protein in the patient'"'"'s samples that is above the average level of soluble VEGF-R2 protein in the control samples is indicative of an activated VEGF pathway and the presence of disease in the patient.

28. The method of claim 27, wherein said immunological detection and quantification of steps (a) and (b) is by an immunoassay in the form of a sandwich ELISA or equivalent assay.